Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Daewon Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	590,698	598,162	526,952	478,885	354,176	308,501
Other Revenue	-0	-0	-0	-0	-0	0
Revenue	590,698	598,162	526,952	478,885	354,176	308,501
Revenue Growth (YoY)	-0.55%	13.51%	10.04%	35.21%	14.81%	-2.93%
Cost of Revenue	324,993	312,188	271,808	243,038	179,630	144,354
Gross Profit	265,706	285,974	255,144	235,847	174,546	164,147
Selling, General & Admin	233,276	226,957	198,507	173,719	144,585	135,522
Research & Development	22,297	21,926	18,207	12,646	-	-
Amortization of Goodwill & Intangibles	2,122	2,082	1,034	1,505	988.79	784.59
Other Operating Expenses	3,184	3,242	2,951	2,320	8,009	2,080
Operating Expenses	266,057	259,297	222,911	192,943	155,243	140,168
Operating Income	-351.12	26,677	32,233	42,904	19,303	23,979
Interest Expense	-7,646	-9,306	-4,614	-3,683	-2,078	-1,182
Interest & Investment Income	1,138	1,664	1,416	1,259	532.2	281.72
Earnings From Equity Investments	1,245	996.46	509.42	860.08	382.62	517.27
Currency Exchange Gain (Loss)	89.19	156.06	121.26	219.82	71.59	-91.69
Other Non Operating Income (Expenses)	-451.63	1,354	672.88	23.15	906.98	-1,139
EBT Excluding Unusual Items	-5,976	21,541	30,338	41,583	19,119	22,365
Gain (Loss) on Sale of Investments	-1,247	-1,149	-61.5	-752.76	-870.39	1,990
Gain (Loss) on Sale of Assets	-482.66	-312.09	149.95	45.71	-0.86	2.34
Asset Writedown	-2,263	-3,921	-4,597	-2,154	-1,111	-715.77
Pretax Income	-9,968	16,159	25,830	38,722	17,136	23,642
Income Tax Expense	8,730	6,055	2,367	8,065	10,525	6,443
Earnings From Continuing Operations	-18,698	10,104	23,463	30,657	6,611	17,198
Earnings From Discontinued Operations	-1,231	-1,059	-	-	-	-
Net Income to Company	-19,930	9,045	23,463	30,657	6,611	17,198
Minority Interest in Earnings	3,893	5,165	453.67	1,287	378.15	441.9
Net Income	-16,037	14,210	23,917	31,944	6,989	17,640
Net Income to Common	-16,037	14,210	23,917	31,944	6,989	17,640
Net Income Growth	-	-40.59%	-25.13%	357.08%	-60.38%	-35.36%
Shares Outstanding (Basic)	21	21	21	21	21	21
Shares Outstanding (Diluted)	21	22	22	22	21	21
Shares Change (YoY)	-1.15%	-	-0.98%	3.09%	-0.58%	-1.06%
EPS (Basic)	-748.28	667.43	1139.91	1509.75	329.36	826.54
EPS (Diluted)	-748.28	667.43	1110.44	1478.37	329.36	826.54
EPS Growth	-	-39.90%	-24.89%	348.86%	-60.15%	-34.66%
Free Cash Flow	17,352	-4,829	39,446	18,405	18,309	13,605
Free Cash Flow Per Share	809.63	-222.96	1821.12	841.34	862.87	637.47
Dividend Per Share	300.000	300.000	-	-	194.175	155.340
Dividend Growth	-	-	-	-	25.00%	-33.45%
Gross Margin	44.98%	47.81%	48.42%	49.25%	49.28%	53.21%
Operating Margin	-0.06%	4.46%	6.12%	8.96%	5.45%	7.77%
Profit Margin	-2.71%	2.38%	4.54%	6.67%	1.97%	5.72%
Free Cash Flow Margin	2.94%	-0.81%	7.49%	3.84%	5.17%	4.41%
EBITDA	22,066	46,771	49,794	62,272	37,109	39,652
EBITDA Margin	3.74%	7.82%	9.45%	13.00%	10.48%	12.85%
D&A For EBITDA	22,417	20,095	17,561	19,368	17,805	15,674
EBIT	-351.12	26,677	32,233	42,904	19,303	23,979
EBIT Margin	-0.06%	4.46%	6.12%	8.96%	5.45%	7.77%
Effective Tax Rate	-	37.47%	9.16%	20.83%	61.42%	27.25%
Advertising Expenses	-	33,923	29,701	27,199	26,272	23,013

Source: S&P Global Market Intelligence. Standard template. Financial Sources.